Their primary role is medical: improving weight-related health, blood sugar control and cardiometabolic risk
A CMS payment demonstration is expanding access for Medicare and Medicaid beneficiaries at reduced costs beginning mid-2026
Use photos or measurements to track changes beyond just weight
Information on requesting access to datasets can be found at www.novonordisk-trials.com
differences reflect manufacturing source, not chemical composition
76,81,96,97 The main factor contributing to the lack of greater investment in lixisenatide and other short-acting agents for MASLD may be their influence on metabolic function, including pharmacokinetic differences induced by a single-dose method and their effects on gastric emptying, 91 which could limit their effectiveness in improving glycolipid metabolism